Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Gastroenterol Hepatol ; 34(8): 1432-1440, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-30828861

RESUMEN

BACKGROUND AND AIM: The pathological features of non-alcoholic steatohepatitis (NASH) have not been determined, so fundamental treatment has not been established. Adipose-tissue-derived stromal/stem cells (ADSCs) are beneficial for repair/regenerative therapy of impaired organs because of their immuno-modulatory capability. In this study, we assessed how liver damage progresses during the early development phase of the murine NASH model and investigated whether ADSCs are preventatively efficacious against the fibrosis progression of NASH. METHODS: C57BL/6J mice were fed with atherogenic high fat or high-fat diet 60 developing into NASH or simple steatosis. Their hepatic inflammatory cells (HICs) were analyzed by cDNA microarray. NASH mice were treated with ADSCs injected into spleen when hepatic inflammation was initially observed, and liver samples were analyzed. The effect of ADSCs on the mice hepatic stellate cell (HSC) line stimulated by recombinant IL-17 and HICs from NASH mice was analyzed. RESULTS: The gene expression features of HICs implicated as humoral cytokine mediators of lymphoid cells during NASH development, compared with a simple steatosis model. One of the featured cytokines was IL-17. The development of hepatic fibrosis was alleviated when NASH mice were treated with ADSCs as well as treated with anti-IL-17 antibody, and the frequency of IL-17-secreting HICs decreased. NASH-HICs enhanced proliferation of HSCs, in which proliferation was sensitive to IL-17 stimulation. The stimulatory effect of NASH-HICs on the activation of HSCs was attenuated by co-culture with ADSCs. CONCLUSION: ADSCs treatment prevented progression of NASH fibrosis by suppressing IL-17-mediated inflammation, which was associated with HSCs activation.


Asunto(s)
Tejido Adiposo/trasplante , Mediadores de Inflamación/metabolismo , Interleucina-17/metabolismo , Cirrosis Hepática Experimental/prevención & control , Hígado/metabolismo , Enfermedad del Hígado Graso no Alcohólico/prevención & control , Trasplante de Células Madre , Células Madre/metabolismo , Tejido Adiposo/citología , Animales , Línea Celular , Proliferación Celular , Técnicas de Cocultivo , Dieta Alta en Grasa , Progresión de la Enfermedad , Femenino , Células Estrelladas Hepáticas/inmunología , Células Estrelladas Hepáticas/metabolismo , Células Estrelladas Hepáticas/patología , Mediadores de Inflamación/inmunología , Interleucina-17/inmunología , Interleucina-17/farmacología , Hígado/inmunología , Hígado/patología , Cirrosis Hepática Experimental/inmunología , Cirrosis Hepática Experimental/metabolismo , Cirrosis Hepática Experimental/patología , Ratones Endogámicos C57BL , Enfermedad del Hígado Graso no Alcohólico/inmunología , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/patología , Células Madre/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA